Evaluation of source displacement and dose-volume changes after permanent prostate brachytherapy with stranded seeds

Radiotherapy and Oncology

Volumn 84, Issue 2, 2007, Pages 190-196

  Pinkawa, Michael ^a   Asadpour, Branka ^a   Gagel, Bernd ^a   Piroth, Marc D ^a   Borchers, Holger ^b   Jakse, Gerhard ^b   Eble, Michael J ^a  

^a Department of Radiation Oncology ^*

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

125I; Brachytherapy; Postimplant dosimetry; Prostate neoplasm; Prostate oedema

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DOSIMETRY; EDEMA; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; PELVIC GIRDLE; POSTOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOMETRY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34548126489     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.07.014     Document Type: Article

References (35)

1. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 62 (2005) 981-987
2. Ash D., Al-Qaisieh B., Bottomley D., et al. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer. Radiother Oncol 75 (2005) 303-306
3. 90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol 79 (2006) 185-189
4. Ash D., Flynn A., Battermann J., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57 (2000) 315-321
5. Battermann J.J., Boon T.A., and Moerland M.A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71 (2004) 23-28
6. Beyer D.C., McKeough T., Thomas T., et al. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299-1305
7. Bottomley D., Ash D., Al-Qaisieh B., et al. Side effects of permanent I-125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 82 (2007) 46-49
8. Chen Z., Yue N., Wang X., et al. Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution. Int J Radiat Oncol Biol Phys 47 (2000) 1405-1419
9. Choi S., Merrick G., Cavanagh W., et al. Rectal doses can be safely minimized without affecting the likelihood of cure after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63 (2005) S325-S326
10. Coakley F.V., Hricak H., Wefer A.E., et al. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 219 (2001) 817-821
11. Fuller D.B., Koziol J.A., and Feng A.C. Prostate brachytherapy seed migration and dosimetry: an analysis of stranded sources and other potential predictive factors. Brachytherapy 3 (2004) 10-19
12. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
13. Hinerman-Mulroy A., Merrick G.S., Butler W.M., et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1367-1382
14. International Commission on Radiation Units and Measurements (ICRU). Prescribing, recording, and reporting photon beam therapy. ICRU report 50. Bethesda, MD:ICRU; 1993. p. 1-8.
15. McLaughlin P.W., Feng M., Berri S., and Narayana V. Improved ct prostate apex definition by genitourinary diaphragm recognition. Int J Radiat Oncol Biol Phys 66 (2006) S336
16. McLaughlin P.W., Narayana V., Pan C., et al. Comparison of day 0 and day 14 dosimetry for permanent implants using stranded seeds. Int J Radiat Oncol Biol Phys 64 (2006) 144-150
17. Merrick G.S., Butler W.M., Dorsey A.T., et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 46 (2000) 215-220
18. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
19. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society Recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
20. Pinkawa M., Fischedick K., Gagel B., et al. Association of neoadjuvant hormonal therapy with adverse health-related quality-of-life after permanent I-125 brachytherapy for localized prostate cancer. Urology (2006) 104-109
21. Pinkawa M., Gagel B., Holy R., et al. Reliabilty of CT-based postimplant dose values in interstitial permanent brachytherapy. Radiother Oncol 71 (2004) 122
22. Pinkawa M., Gagel B., Piroth M.D., et al. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. Strahlenther Onkol 182 (2006) 525-530
23. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
24. Potters L., Torre T., Fearn P.A., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1235-1242
25. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 40 (1998) 1111-1115
26. Reed D.R., Wallner K., Ford E., et al. Effect of post-implant edema on prostate brachytherapy treatment margins. Int J Radiat Oncol Biol Phys 63 (2005) 1469-1473
27. Salembier C., Lavagnini P., Nickers P., et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 83 (2007) 3-10
28. 125I prostate brachytherapy using rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
29. Taussky D., Austen L., Toi A., et al. Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. Int J Radiat Oncol Biol Phys 62 (2005) 974-980
30. Taussky D., Yeung I., Williams T., et al. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 358-363
31. Waterman F.M., and Dicker A.P. Effect of post-implant edema on the rectal dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 45 (1999) 571-576
32. 103Pd prostate seed implants. Int J Radiat Oncol Biol Phys 45 (1999) 1063-1072
33. 103Pd seed implant of prostate. Int J Radiat Oncol Biol Phys 43 (1999) 447-454
34. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
35. Zelefsky M.J., Yamada Y., Cohen G., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 65-70